In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study

2018 ◽  
Vol 28 (3) ◽  
pp. e12721 ◽  
Author(s):  
Philipp O. Valko ◽  
Bernd Roschitzki ◽  
Wolfgang Faigle ◽  
Jonas Grossmann ◽  
Christian Panse ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Cerebrospinal Fluid Biomarkers ◽  
Proteomics Study

Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

2020 ◽  
Vol 45 ◽  
pp. 102391 ◽  
Author(s):  
Mie Reith Mahler ◽  
Helle Bach Søndergaard ◽  
Sophie Buhelt ◽  
Marina Rode von Essen ◽  
Jeppe Romme Christensen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Cerebrospinal Fluid Biomarkers

scholarly journals The cerebrospinal fluid in multiple sclerosis: far beyond the bands

2017 ◽  
Vol 15 (1) ◽  
pp. 100-104 ◽  
Author(s):  
Renan Barros Domingues ◽  
Gustavo Bruniera Peres Fernandes ◽  
Fernando Brunale Vilela de Moura Leite ◽  
Charles Peter Tilbery ◽  
Rodrigo Barbosa Thomaz ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Oligoclonal Bands ◽  
Fluid Analysis ◽  
Cerebrospinal Fluid Biomarkers ◽  
Therapeutic Decisions ◽  
Neuroimaging Data ◽  
Chemokine Ligand ◽  
New Biomarkers

ABSTRACT The cerebrospinal fluid analysis has been employed for supporting multiple sclerosis diagnosis and ruling out the differential diagnoses. The most classical findings reflect the inflammatory nature of the disease, including mild pleocytosis, mild protein increase, intrathecal synthesis of immunoglobulin G, and, most typically, the presence of oligoclonal bands. In recent years, new biomarkers have emerged in the context of multiple sclerosis. The search for new biomarkers reflect the need of a better evaluation of disease activity, disease progression, and treatment efficiency. A more refined evaluation of disease and therapy status can contribute to better therapeutic choices, particularly in escalation of therapies. This is very relevant taking into account the availability of a greater number of drugs for multiple sclerosis treatment in recent years. In this review, we critically evaluate the current literature regarding the most important cerebrospinal fluid biomarkers in multiple sclerosis. The determination of biomarkers levels, such as chemokine ligand 13, fetuin A, and mainly light neurofilament has shown promising results in the evaluation of this disease, providing information that along with clinical and neuroimaging data may contribute to better therapeutic decisions.

scholarly journals Cerebrospinal Fluid and Blood Biomarkers of Neuroaxonal Damage in Multiple Sclerosis

2011 ◽  
Vol 2011 ◽  
pp. 1-18 ◽  
Author(s):  
Irena Dujmovic
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Future Research ◽  
Clinical Parameters ◽  
Disease Course ◽  
Scientific Interest ◽  
Blood Biomarkers ◽  
Response Strategies ◽  
Cerebrospinal Fluid Biomarkers ◽  
Existing Data

Following emerging evidence that neurodegenerative processes in multiple sclerosis (MS) are present from its early stages, an intensive scientific interest has been directed to biomarkers of neuro-axonal damage in body fluids of MS patients. Recent research has introduced new candidate biomarkers but also elucidated pathogenetic and clinical relevance of the well-known ones. This paper reviews the existing data on blood and cerebrospinal fluid biomarkers of neuroaxonal damage in MS and highlights their relation to clinical parameters, as well as their potential predictive value to estimate future disease course, disability, and treatment response. Strategies for future research in this field are suggested.

Multiple Sclerosis: Monitoring Disease Activity and Progression

2017 ◽  
Author(s):  
Pavan Bhargava ◽  
Shiv Saidha
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Cerebrospinal Fluid ◽  
Nervous System ◽  
Disease Activity ◽  
Cerebrospinal Fluid Biomarkers ◽  
The Central Nervous System ◽  
Degenerative Disorder ◽  
Clinical Measures ◽  
Assessment Strategies

Multiple sclerosis is a chronic inflammatory and degenerative disorder of the central nervous system. Measuring disease activity and progression are an integral part of the management of the disorder. A number of different approaches, including clinical measures, imaging metrics, and blood/cerebrospinal fluid biomarkers have been investigated for their utility in monitoring disease activity and progression. Each of these different approaches has certain advantages, as well as limitations, and this chapter provides an overview of these different assessment strategies.

scholarly journals Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

2016 ◽  
Vol 23 (1) ◽  
pp. 62-71 ◽  
Author(s):  
Lenka Novakova ◽  
Markus Axelsson ◽  
Mohsen Khademi ◽  
Henrik Zetterberg ◽  
Kaj Blennow ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Enzyme Linked Immunosorbent Assay ◽  
Csf Biomarkers ◽  
First Line ◽  
Additional Measure ◽  
Neurofilament Light ◽  
Cerebrospinal Fluid Biomarkers ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Degenerative Processes

Background: The disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) vary in their mode of action and when therapies are changed, the consequences on inflammatory and degenerative processes are largely unknown. Objective: We investigated the effect of switching from other DMTs to fingolimod on cerebrospinal fluid (CSF) biomarkers. Methods: 43 RRMS patients were followed up after 4–12 months of fingolimod treatment. Concentrations of C-X-C motif chemokine 13 (CXCL13), chemokine (C-C motif) ligand 2 (CCL2), chitinase-3-like protein 1 (CHI3L1), glial fibrillary acidic protein (GFAP), neurofilament light protein (NFL), and neurogranin (NGRN) were analyzed by enzyme-linked immunosorbent assay (ELISA), while chitotriosidase (CHIT1) was analyzed by spectrofluorometry. Results: The levels of NFL, CXCL13, and CHI3L1 decreased ( p < 0.05) after fingolimod treatment. Subgroup analysis revealed a reduction in NFL ( p < 0.001), CXCL13 ( p = 0.001), CHI3L1 ( p < 0.001), and CHIT1 ( p = 0.002) in patients previously treated with first-line therapies. In contrast, the levels of all analyzed biomarkers were essentially unchanged in patients switching from natalizumab. Conclusion: We found reduced inflammatory activity (CXCL13, CHI3L1, and CHIT1) and reduced axonal damage (NFL) in patients switching from first-line DMTs to fingolimod. Biomarker levels in patients switching from natalizumab indicate similar effects on inflammatory and degenerative processes. The CSF biomarkers provide an additional measure of treatment efficacy.

Sign in / Sign up

Export Citation Format

Share Document